|
TOPICS:
MCL and Aggressive
Lymphoma | CLL / SLL | T-cell and Hodgkins | High-Risk / Transformed
Follicular - new types and indications
 TOPIC
SEARCH ~
Web
Here we link to study protocols investigating the safety and
efficacy of RIT for indications beyond what RIT is already
approved for.
Each protocol will provide contact and
location information.
Completed studies are included as these might be considered
as Off-Protocol therapies.
MCL and Aggressive Lymphoma:
.gif) |
Phase 1 Study of Radio-sensitization Using
Bortezomib (Velcade) for Relapsed Mantle Cell or Aggressive
Lymphoma Patients in Radioimmunotherapy
http://bit.ly/cfOftA
|
|
|
Zevalin-BEAM/BEAC With Autologous Stem Cell
Support as Consolidation in First Line Treatment of Mantle Cell
Lymphoma http://bit.ly/bbba12
|
|
|
Targeted Intensification Utilizing ZBEAM
Followed by Autologous Stem Cell Transplantation (ASCT) in
Patients With High-grade B-Cell Lymphoma (ZBEAM2)
|
|
|
Study of 90Y-DOTA-hLL2 as a Consolidation
Therapy After R-CHOP in Patients With Diffuse Large B-Cell
Lymphoma http://bit.ly/bxEC8Z
|
|
|
Zevalin Twice in Aggressive Non-Hodgkin
Lymphoma http://bit.ly/daY0cI
|
CLL / SLL:
|
|
Study Looking at Effectiveness of
131-Tositumomab (Bexxar) Consolidation for Patients With CLL or
SLL http://bit.ly/cJQCV7
|
T-cell and Hodgkins lymphoma:
|
|
Iodine I 131 Monoclonal Antibody BC8
(anti-cd45) and Autologous Stem Cell Transplant in Treating
Patients With Lymphoma That Has Relapsed or Not Responded to
Treatment http://bit.ly/c2LbFW
(Hodgkin lymphoma - Must have
CD45+ cells adjacent to the Reed Sternberg cells)
|
|
|
131I anti-CD45 radioimmunotherapy effectively
targets and treats T-cell non-Hodgkin lymphoma
http://bit.ly/9TQAW9
|
High risk b-cell lymphoma / transformed lymphoma:
|
|
High Dose Chemotherapy With Monoclonal Antibody
and Radioimmunotherapy for High-Risk B-Cell NHL
http://bit.ly/bO0uuF
|
|
|
Safety and Efficacy of Bexxar Therapy in the
Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous
Transplant http://bit.ly/awVp5H
|
|
|
Pivotal Study of Iodine I 131 Tositumomab for
Chemotherapy-refractory Low-grade or Transformed Low-grade
B-cell Lymphoma (completed)
"The results from Phase 1/2
(RIT-I-000) and Phase 2 (RIT-II-001) studies of Tositumomab and
Iodine I 131 Tositumomab (TST/I-131 TST) demonstrated that TST/
I-131 TST produced a high response rate in patients with
chemotherapy-relapsed/refractory, low-grade or transformed
low-grade Non-Hodgkin's Lymphoma (NHL). On the basis of these
results this study was designed to compare the efficacy of TST/
I-131 TST to the last qualifying chemotherapy regimen in
patients with chemotherapy-refractory, low-grade or transformed
low-grade NHL." |
|
|
CpG 7909 (immune adjuvant), Rituximab, and
Zevalin in Treating Patients With NHL That is Recurrent or Did
Not Respond to Previous Treatment
http://bit.ly/9efFdm |
|
|
Safety and Efficacy of 90Y Zevalin in
Nonmyeloablative (mini) Transplantation for Lymphoid
Malignancies http://bit.ly/diXeWj
|
Orbital b-cell lymphoma:
|
|
Radioimmunotherapy With 90Y Zevalin for Orbital
Lymphoma (completed) |
Follicular -new type of RIT:
|
|
Combination Veltuzumab and Fractionated 90Y-
Epratuzumab Radioimmunotherapy in Follicular Lymphoma
http://bit.ly/c80PPu
|
|
|
Bexxar or Zevalin in Treating Patients With
Non-Hodgkin's Lymphoma http://bit.ly/asKpWL
(Not a new indication, but a test to compare efficacy and safety
... what a novel idea : ) |
|
|
Rituximab, Combination Chemotherapy, and
Zevalin in Treating Patients With Stage I or Stage II Lymphoma
(completed) |
|
|
WM - Waldenstrom's Macroglobulinemia
|
|
|
Radiolabeled Monoclonal Antibody Therapy Plus
Peripheral Stem Cell Transplantation in Treating Patients With
Lymphoma or Waldenstrom's Macroglobulinemia (completed)
|
Other
|
|
Donor Peripheral Blood Stem Cell Transplant and
Pretargeted Radioimmunotherapy in Treating Patients With
High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic
Leukemia, or Myelodysplastic Syndrome
http://bit.ly/cDGLxa
|
Resources
-
Clinical Trials Search
PAL
|
